The latest evidences strongly suggest that complex molecular alterations coupled with changes in the tumor microenvironment may substantially contribute to the clinical efficacy of EGFR antagonists, even in CRC that are both KRAS and NRAS wild type [5,6,7,8,9,10,14]. The gene discussed is EGFR; the disease is colorectal carcinoma.